Physician profile
Marlen E Martinez
NPI 1629543038
$1,311.39
in general payments reported to CMS, 2019-2025
14 companies · $129 in 2025
The $129 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $222 · 2022: $314 · 2023: $331 · 2024: $314 · 2025: $129.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $775.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $775.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $421.36 | 2021-2024 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $255.26 | 2021-2024 | Caplyta |
| Exact Sciences Corporation | $140.47 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $90.91 | 2022-2023 | Abilify Maintena, Rexulti |
| Amgen INC. | $82.23 | 2023-2024 | Repatha, Otezla |
| Lundbeck LLC | $63.09 | 2022-2024 | Rexulti |
| Horizon Therapeutics Plc | $52.21 | 2022 | |
| Lilly USA, LLC | $51.28 | 2023-2024 | Mounjaro |
| Abbvie INC. | $38.00 | 2022 | |
| Pfizer INC. | $29.71 | 2021 | |
| Novo Nordisk INC | $25.01 | 2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $22.91 | 2022 | |
| Alkermes, INC. | $22.06 | 2024 | Aristada, Lybalvi |
| Sunovion Pharmaceuticals INC. | $16.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marlen Martinez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.